ORMP - Oramed Pharmaceuticals Inc. Stock Analysis & Valuation

Oramed Pharmaceuticals Inc. (ORMP) trades at $4.11 with an EquitAI Valuation DNA score of 3/10 and Quality score of 8/10. The company's trailing P/E ratio is 1.0x. These scores evaluate balance sheet leverage, free cash flow generation, and fundamental multiples against historical benchmarks.

Wall Street analysts have a consensus 12-month price target of $7.0 for Oramed Pharmaceuticals Inc. (ORMP), representing an implied 70.3% upside from its current trading level of $4.11 with an average rating of Buy based on 1 analyst rating. Because this forecast is provided by a single analyst, it represents limited coverage and may reflect historical or isolated expectations rather than a broad consensus. EquitAI benchmarks analyst consensus projections against intrinsic Financial DNA valuation pillars.

Oramed Pharmaceuticals Inc. has an indicated annual dividend yield of 6.08%. Dividend stability is factored into its Income DNA pillar alongside free cash flow coverage.

EquitAI provides quantitative financial research, algorithmic DNA scores, and SEC contextual analytics for informational and research purposes. It does not constitute personalized financial advice or broker-dealer investment recommendations.